https://www.selleckchem.com/pr....oducts/2-aminoethane
Metabolic syndrome (MetS) is a clustering of several cardiovascular risk factors that include obesity, dyslipidemia, hypertension and high blood glucose, and often requires multidrug pharmacological interventions. The management of MetS therefore requires high healthcare cost, and can result in poor drug treatment compliance. Hence drug therapies that have pleiotropic beneficial effects may be of value. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are the newest anti-diabetic drugs that mimic incretin effects in the b
Like
Comment
Share
